Sarepta Therapeutics (SRPT) : Traders are bullish on Sarepta Therapeutics (SRPT) as it has outperformed the S&P 500 by a wide margin of 12.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.02%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.57% in the last 1 week, and is up 9.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.46% and the 50-Day Moving Average is 11.51%.The 200 Day SMA reached 28.31% Sarepta Therapeutics, Inc. is up 62.15% in the last 3-month period. Year-to-Date the stock performance stands at -27.03%.
Sarepta Therapeutics (SRPT) stock is expected to deviate a maximum of $18.79 from the average target price of $24.18 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $60 and the most muted being $4.
Company shares have received an average consensus rating of Hold for the current week Sarepta Therapeutics (NASDAQ:SRPT): stock was range-bound between the intraday low of $27.9901 and the intraday high of $29.93 after having opened at $29.4 on Fridays session. The stock finally closed in the red at $29.4, a loss of -6.23%. The stock remained in the red for the whole trading day. The total traded volume was 4,374,537 shares. The stock failed to cross $29.93 in Fridays trading. The stocks closing price on Thursday was $28.15.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.